Analyst Price Targets — COGT
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 17, 2026 11:03 am | — | Piper Sandler | $55.00 | $37.93 | TheFly | Cogent Biosciences price target raised to $55 from $52 at Piper Sandler |
| August 12, 2026 10:51 am | Michael Schmidt | Guggenheim | $52.00 | $38.70 | TheFly | Cogent Biosciences price target raised to $52 from $45 at Guggenheim |
| June 1, 2026 11:31 am | Laura Prendergast | Stifel Nicolaus | $45.00 | $34.96 | StreetInsider | Cogent (COGT) Reiterated at Buy by Stifel After ASCO Presentation on Bezuclastinib |
| May 6, 2026 10:14 am | Robert Burns | H.C. Wainwright | $55.00 | $36.98 | TheFly | Cogent Biosciences price target raised to $55 from $52 at H.C. Wainwright |
| February 19, 2026 1:55 pm | — | Robert W. Baird | $35.00 | $38.29 | TheFly | Cogent Biosciences price target raised to $35 from $34 at Baird |
| February 18, 2026 11:43 am | — | Piper Sandler | $52.00 | $37.62 | TheFly | Cogent Biosciences price target raised to $52 from $39 at Piper Sandler |
| January 7, 2026 5:41 am | Michael Yee | UBS | $60.00 | $34.78 | StreetInsider | UBS Starts Cogent (COGT) at Buy |
| January 6, 2026 11:09 am | — | H.C. Wainwright | $52.00 | $34.26 | TheFly | Cogent Biosciences price target raised to $52 from $50 at H.C. Wainwright |
| December 8, 2025 4:03 pm | — | Jefferies | $48.00 | $39.97 | TheFly | Cogent Biosciences price target raised to $48 from $45 at Jefferies |
| November 11, 2025 9:27 am | Chris Raymond | Raymond James | $60.00 | $32.46 | StreetInsider | Cogent (COGT) PT Raised to $60 at Raymond James, 'remains our Analyst Current Favorite' |
Latest News for COGT
NDA supported by positive results from the APEX pivotal trial demonstrating clinically meaningful responses and evidence of disease modification in patients with AdvSM
Cogent Biosciences is positioned to commercialize bezuclastinib across three indications, leveraging a single precision molecule for multi-market entry. Positive pivotal data in GIST, NonAdvSM, and AdvSM underpin three NDAs, with regulatory decisions expected between late 2026 and early 2027. COGT's commercial infrastructure and $865.9M liquidity provide a runway through 2028, supporting launch and early…
Deutsche Bank AG acquired a new stake in shares of Cogent Biosciences, Inc. (NASDAQ: COGT) during the undefined quarter, according to the company in its most recent Form 13F filing with the SEC. The firm acquired 266,584 shares of the technology company's stock, valued at approximately $10,317,000. Deutsche Bank AG owned approximately 0.16%
Handelsbanken Fonder AB acquired a new position in shares of Cogent Biosciences, Inc. (NASDAQ: COGT) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 44,600 shares of the technology company's stock, valued at approximately $1,726,000. A number of other institutional
Cogent Biosciences (COGT) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for COGT.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.